This is a routine quarterly update for a pre-revenue clinical-stage biotech with no material surprises. The stock is likely to trade on KOMODO-1 trial data readouts, not quarterly financials. Monitor for initial proof-of-concept data expected within the existing cash runway timeline.
Price Chart
Executive Summary
Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lower R&D and G&A expenses. Cash burn continues, with cash reserves declining from $107.6M to $92.8M, but the company maintains runway into H2 2028. The KOMODO-1 trial for BBI-940 is enrolling, but the stock is a pre-revenue clinical-stage biotech with no revenue or earnings, making this a routine operational update with no material surprise.
Key Financial Metrics
Key Facts
- Net loss of $13.6M in Q1 2026 vs $15.8M in Q1 2025, a 14% improvement
- Cash, cash equivalents, and short-term investments totaled $92.8M as of March 31, 2026
- Cash runway expected into H2 2028, through anticipated clinical proof-of-concept readout for KOMODO-1
- R&D expenses decreased to $9.7M from $12.1M year-over-year
- G&A expenses decreased to $4.7M from $5.2M year-over-year
- KOMODO-1 first-in-human trial of BBI-940 is open for enrollment
- No revenue reported; company is a pre-revenue clinical-stage oncology biotech
Financial Impact
Net loss improved by $2.2M YoY to $13.6M; cash burn of $14.7M in Q1 2026
Risk Factors
- Clinical trial failure or delay for BBI-940
- Cash burn rate may accelerate if enrollment or trial costs increase
- No revenue and no approved products; fully dependent on clinical success
- Potential need for future dilutive financing if cash runway shortens
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213269 |
| Document: bold-20260508.htm | 0001193125-26-213269 |
| Document: 0001193125-26-213269-index-headers.html | 0001193125-26-213269 |
| Document: 0001193125-26-213269-index.html | 0001193125-26-213269 |
| Document: 0001193125-26-213269.txt | 0001193125-26-213269 |
| 8-K Data (Synthetic) | 0001193125-26-213269 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 8, 2026 17d ago | S-4 | $2.53 | awaiting T+20 | — | $2.40 (+5.14%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.40 (−14.59%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.40 (−4.38%) |
Jul 6, 2026 15w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.40 (−4.00%) |
Jun 29, 2026 16w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.40 (−4.00%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.40 (+66.67%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.40 (−66.67%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.40 (+50.00%) |
Apr 13, 2026 27w ago | 8-K | $1.56 $1.55 | ▲ +0.64% | ▲ +6.94% | $2.40 (−53.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers